AstraZeneca Makes Good On Vow To Build CV Pipeline With AlphaCore Buy

AstraZeneca’s biologics unit MedImmune acquired AlphaCore Pharma, the developer of an early-stage asset with a novel mechanism for removing cholesterol from the body and raising “good” HDL cholesterol.